secwatch.observer — SEC 8-K summary
======================================

Issuer:     Checkpoint Therapeutics, Inc. (—)
CIK:        0001651407
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001104659-25-021973
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.03, 8.01, 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Checkpoint Therapeutics to be acquired by Sun Pharma for $4.10/share plus CVR
-----------------------------------------------------------------------------

- Total transaction value up to ~$416M; $4.10 per share cash plus CVR up to $0.70.
- CVR pays up to $0.70 based on EMA approval of cosibelimab in EU or key countries within 36 months of filing.
- Fortress Biotech (11.2% of shares, majority voting power) agrees to vote in favor and waive appraisal.
- Merger subject to stockholder vote, HSR clearance, and other conditions; termination fee of $12.5M.
- Company adopted exclusive forum bylaw for derivative and Securities Act claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651407/000110465925021973/0001104659-25-021973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651407/000110465925021973/tm258581d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-021973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer